RS50104B - Nova oralna formulacija za 5-th4 agoniste ili antagoniste - Google Patents

Nova oralna formulacija za 5-th4 agoniste ili antagoniste

Info

Publication number
RS50104B
RS50104B YUP-87/01A YU8701A RS50104B RS 50104 B RS50104 B RS 50104B YU 8701 A YU8701 A YU 8701A RS 50104 B RS50104 B RS 50104B
Authority
RS
Serbia
Prior art keywords
agonists
antagonists
oral formulation
sodium
new oral
Prior art date
Application number
YUP-87/01A
Other languages
English (en)
Inventor
Karel De Bruijn
Gunter Engel
Hans-Jurgen Pfannkuche
Michael Thewissen
Christian Vitzling
Othmar Zuger
Original Assignee
Novartis Ag.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50104(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9818340.3A external-priority patent/GB9818340D0/en
Priority claimed from GBGB9823477.6A external-priority patent/GB9823477D0/en
Priority claimed from GBGB9910320.2A external-priority patent/GB9910320D0/en
Priority claimed from GBGB9911059.5A external-priority patent/GB9911059D0/en
Application filed by Novartis Ag., filed Critical Novartis Ag.,
Publication of YU8701A publication Critical patent/YU8701A/sh
Publication of RS50104B publication Critical patent/RS50104B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Cosmetics (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Čvrsta oralna farmaceutska kompozicija koja sadrži jedinjenje A ili njene soli; obuhvata desintegrant, prisutan u količini od barem 15% svedeno na ukupnu težinu kompozicije, gde je desintegrant član koji je odabran iz grupe koju sačinjavaju krospovidon, preželatinizirani skrob, natrijum skrob glikolat, natrijum karboksimetilceluloza, kalcijum karboksimetilceluloza, natrijum alginat i njihova smeša. Prijava sadrži još 19 patentnih zahteva.
YUP-87/01A 1998-08-21 1999-08-19 Nova oralna formulacija za 5-th4 agoniste ili antagoniste RS50104B (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9818340.3A GB9818340D0 (en) 1998-08-21 1998-08-21 Organic compounds
GBGB9823477.6A GB9823477D0 (en) 1998-10-27 1998-10-27 Organic compounds
GBGB9910320.2A GB9910320D0 (en) 1999-05-05 1999-05-05 Organic compounds
GBGB9911059.5A GB9911059D0 (en) 1999-05-12 1999-05-12 Organic compounds

Publications (2)

Publication Number Publication Date
YU8701A YU8701A (sh) 2003-12-31
RS50104B true RS50104B (sr) 2009-01-22

Family

ID=27451823

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-87/01A RS50104B (sr) 1998-08-21 1999-08-19 Nova oralna formulacija za 5-th4 agoniste ili antagoniste

Country Status (30)

Country Link
US (4) US20030236183A1 (sr)
EP (1) EP1104289B1 (sr)
JP (1) JP4048024B2 (sr)
KR (1) KR100529659B1 (sr)
CN (2) CN1165293C (sr)
AT (1) ATE316782T1 (sr)
AU (4) AU762829B2 (sr)
BG (1) BG65322B1 (sr)
BR (1) BR9913135A (sr)
CA (1) CA2338794C (sr)
CZ (1) CZ300647B6 (sr)
DE (1) DE69929703T2 (sr)
DK (1) DK1104289T3 (sr)
EE (1) EE05054B1 (sr)
ES (1) ES2257869T3 (sr)
FR (3) FR2782454B1 (sr)
HK (1) HK1038179A1 (sr)
HR (1) HRP20010123B1 (sr)
HU (1) HU228179B1 (sr)
ID (1) ID28510A (sr)
IL (1) IL141236A0 (sr)
IS (1) IS2369B (sr)
IT (1) IT1314185B1 (sr)
NO (1) NO328756B1 (sr)
NZ (1) NZ509832A (sr)
PL (2) PL194069B1 (sr)
RS (1) RS50104B (sr)
SK (1) SK285255B6 (sr)
TR (3) TR200400187T2 (sr)
WO (1) WO2000010526A2 (sr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743820B2 (en) 2000-07-07 2004-06-01 University Of Toledo Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor
AU2002231627A1 (en) * 2000-11-24 2002-06-03 Janssen Pharmaceutica N.V. Use of a triple combination comprising a 5HT3 antagonist, a 5HT4 agonist and a laxative for promoting intestinal lavage
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
EP1598074B1 (en) * 2003-02-28 2019-01-02 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
WO2004085393A1 (en) * 2003-03-25 2004-10-07 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
MY137386A (en) * 2003-07-24 2009-01-30 Novartis Ag Stable modifications of tegaserod hydrogen maleate
US8591974B2 (en) 2003-11-21 2013-11-26 Kraft Foods Global Brands Llc Delivery system for two or more active components as part of an edible composition
US8591973B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition
US8597703B2 (en) 2005-05-23 2013-12-03 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component
US8591968B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Edible composition including a delivery system for active components
US20050112236A1 (en) 2003-11-21 2005-05-26 Navroz Boghani Delivery system for active components as part of an edible composition having preselected tensile strength
US8591972B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for coated active components as part of an edible composition
US8389032B2 (en) 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition having selected particle size
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP3263117A1 (en) 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
EP3332772A1 (en) 2009-10-30 2018-06-13 IX Biopharma Ltd Fast dissolving solid dosage form
WO2013026565A1 (de) 2011-08-20 2013-02-28 Advanced Medical Balloons Trans-analer einlaufkatheter und verfahren zur intermittierenden auslösung einer reflexkoordinierten defäkation
UA118339C2 (uk) * 2012-09-03 2019-01-10 Біогайа Аб Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US552398A (en) * 1895-12-31 Riveting-machine
JP2708803B2 (ja) * 1987-09-02 1998-02-04 中外製薬株式会社 持続放出製剤
DK0472502T3 (da) * 1990-08-24 1995-10-09 Spirig Ag Fremgangsmåde til fremstilling af pellets
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
US5523289A (en) * 1991-04-15 1996-06-04 Abbott Laboratories Pharmaceutical composition
US20020128172A1 (en) * 1991-12-21 2002-09-12 Smithkline Beecham Plc Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
FR2710915B1 (fr) * 1993-10-04 1995-11-24 Synthelabo Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique.
TW270114B (sr) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
EP0804169A4 (en) * 1994-12-01 1998-08-19 Cibus Pharmaceutical Inc NSAID ADMINISTRATION USING A POWDERED HYDROCOLLOID GUM MACHINABLE FROM HIGHER PLANTS
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
FR2753196B1 (fr) * 1996-09-12 1998-10-23 Synthelabo Derives d'indazole tricyclique, leur preparation et leur application en therapeutique
NZ505123A (en) * 1997-12-19 2003-07-25 Smithkline Beecham Corp Process for manufacturing bite-dispersion tablets by compressing medicaments and other ingredients into granulates then compressing the granulates and other ingredients into tablets, and the tablets thereof
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod

Also Published As

Publication number Publication date
ES2257869T3 (es) 2006-08-01
BG65322B1 (bg) 2008-02-29
CN1165293C (zh) 2004-09-08
KR20010079668A (ko) 2001-08-22
FR2782454A1 (fr) 2000-02-25
AU2003248212A1 (en) 2003-10-30
PL200132B1 (pl) 2008-12-31
ATE316782T1 (de) 2006-02-15
CN1589906A (zh) 2005-03-09
AU2006200048A1 (en) 2006-02-02
SK285255B6 (sk) 2006-09-07
CZ300647B6 (cs) 2009-07-08
US20130158092A1 (en) 2013-06-20
WO2000010526A2 (en) 2000-03-02
EP1104289A2 (en) 2001-06-06
ID28510A (id) 2001-05-31
KR100529659B1 (ko) 2005-11-21
US20080075773A1 (en) 2008-03-27
HU228179B1 (en) 2013-01-28
FR2782454B1 (fr) 2005-12-02
CA2338794A1 (en) 2000-03-02
WO2000010526A3 (en) 2000-09-08
CA2338794C (en) 2009-01-20
NZ509832A (en) 2003-11-28
US20030236183A1 (en) 2003-12-25
ITMI991826A0 (it) 1999-08-19
NO20010863D0 (no) 2001-02-20
TR200102259T2 (tr) 2002-06-21
DE69929703T2 (de) 2007-02-22
JP2002523351A (ja) 2002-07-30
HUP0103431A3 (en) 2002-02-28
HUP0103431A2 (hu) 2002-01-28
HRP20010123B1 (en) 2010-11-30
TR200100361T2 (tr) 2001-06-21
HK1038179A1 (en) 2002-03-08
EE200100104A (et) 2002-06-17
NO20010863L (no) 2001-03-26
EP1104289B1 (en) 2006-02-01
AU2009200403A1 (en) 2009-02-26
FR2799123A1 (fr) 2001-04-06
BG105257A (en) 2001-11-30
PL346764A1 (en) 2002-02-25
FR2784899A1 (fr) 2000-04-28
DK1104289T3 (da) 2006-05-15
HRP20010123A2 (en) 2002-02-28
IL141236A0 (en) 2002-03-10
NO328756B1 (no) 2010-05-03
IT1314185B1 (it) 2002-12-06
SK2432001A3 (en) 2001-09-11
FR2784899B1 (fr) 2001-08-17
ITMI991826A1 (it) 2001-02-19
EE05054B1 (et) 2008-08-15
DE69929703D1 (de) 2006-04-13
CZ2001619A3 (en) 2001-05-16
IS5851A (is) 2001-01-20
PL194069B1 (pl) 2007-04-30
JP4048024B2 (ja) 2008-02-13
US20120071537A1 (en) 2012-03-22
AU762829B2 (en) 2003-07-03
IS2369B (is) 2008-06-15
TR200400187T2 (tr) 2006-11-21
BR9913135A (pt) 2001-05-08
FR2799123B1 (fr) 2005-12-02
CN1323200A (zh) 2001-11-21
YU8701A (sh) 2003-12-31
AU5623299A (en) 2000-03-14

Similar Documents

Publication Publication Date Title
RS50104B (sr) Nova oralna formulacija za 5-th4 agoniste ili antagoniste
MEP33708A (en) Pharmaceutical compositions comprising a hmg coa reductase inhibitor
CY1107512T1 (el) Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους
RS53690B1 (sr) Farmaceutske kompozicije koje sadrže levetiracetam i proces za njihovu pripremu
RS51516B (sr) Dodatna heterociklična jedinjenja i njihovo korišćenje kao antagonista metabotropnih receptora glutamata
ATE306261T1 (de) Antithrombosemittel
ME00520B (me) Levodop/karbidop/entakapon farmaceutski preparat
HRP20020198B1 (en) Moxifloxacin formulation containing common salt
BRPI0316532B8 (pt) composições farmacêuticas compreendendo uma droga básica ou ácida, um tensoativo, e um ácido ou base solúvel em água fisiologicamente tolerável
EP1630157A4 (en) ANTAGONIST OF CASR
EP1019045A4 (en) ANTITHROMBOTIC AGENTS
ES2161049T3 (es) Composicion farmaceutica para administracion oral de un derivado de la n-piperidino-3-pirazolcarboxamida, de sus sales y de sus solvatos.
HRP20010243B1 (en) Compositions containing diphosphonic acids
EP1306375A4 (en) SALTS OF BENZIMIDAZOLE DERIVATIVES AND THEIR USE
MXPA04000456A (es) Analogos de prostaglandina como agonistas del receptor ep4.
HRP20010332B1 (en) Pharmaceutical moxifloxacin preparation
DE69931393D1 (de) Antithrombotische amide
ATE273305T1 (de) Thrombin-inhibitoren
PT1007523E (pt) Derivados indole e 2,3-di-ridroindole, sua preparacao e utilizacao
RS50046B (sr) Farmaceutske kompozicije tizoksanida i nitazoksanida
HUP0203226A2 (hu) Hatóanyagként benzamidszármazékot tartalmazó gyógyszerkészítmény
HRP20080521T3 (en) Orodispersible pharmaceutical composition of an antithrombotic compound
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
YU87501A (sh) Farmaceutski kompleksi